By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TARIS Biomedical 

99 Hayden Avenue
Suite 100
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-676-7750 Fax: 781-676-7788



Drug Delivery

Company News
TARIS Biomedical Announces Positive Results From Ph1b Trial Of TAR-200 (Gemristm) In Patients With Muscle Invasive Bladder Cancer 1/6/2017 11:23:41 AM
TARIS Biomedical Launches Second Phase 1b Clinical Trial Of TAR-200 (Gemris) In Patients With Bladder Cancer 8/10/2016 11:35:21 AM
TARIS Biomedical Initiates Phase Ib Clinical Trial Of TAR-200 (Gemris™) In Patients With Muscle-Invasive Bladder Cancer 7/13/2016 10:27:27 AM
After Last Year’s $587.5 Million Deal With Allergan (AGN), TARIS Biomedical Relaunches With $32 Million Investment Round 10/27/2015 7:04:14 AM
Allergan Inc. (AGN) Grabs TARIS Biomedical's Lead Program In Deal Worth $587.5 Million 8/14/2014 6:32:56 AM
TARIS Biomedical, AstraZeneca PLC (AZN) Ink Pact to Research Bladder Cancer Delivery Device 10/16/2013 6:48:25 AM
TARIS Biomedical Secures $12.5 Million in Additional Financing 4/2/2013 6:51:35 AM
TARIS Biomedical to Present at the 32nd Annual SG Cowen and Company Healthcare Conference 3/6/2012 11:06:12 AM
TARIS Biomedical Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients 11/30/2011 9:08:22 AM
TARIS Biomedical Appoints Christopher Searcy as the Company’s Chief Business Officer 7/25/2011 8:43:50 AM